Mirabegron
Mirabegron is a pharmaceutical drug with 100 clinical trials. Currently 9 active trials ongoing. Historical success rate of 94.4%.
Success Metrics
Based on 67 completed trials
Phase Distribution
Phase Distribution
28
Early Stage
18
Mid Stage
44
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
93.1%
67 of 72 finished
6.9%
5 ended early
9
trials recruiting
100
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Using Mirabegron to Control Arrhythmia-1
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
TReating Incontinence for Underlying Mental and Physical Health
Clinical Trials (100)
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Using Mirabegron to Control Arrhythmia-1
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
TReating Incontinence for Underlying Mental and Physical Health
Double j Stent Related Symptoms
Mechanisms for Activation of Beige Adipose Tissue in Humans
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion
Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
MIrabegron and Physiological Function in Cold Environments
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
Activation of Brown Adipose Tissue Metabolism Using Mirabegron
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 100